As product developers move toward 2nd generation gene and cell medicine constructs, the importance of novel gene regulation and promoter elements has emerged.
Bringing synthetic biology to transcriptional regulation could catalyse a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field.
Artificial Intelligence is a hot topic of conversation in pretty much every industry all the way from manufacturing to education.
The past decade has seen a resurgence in the field of cell and gene therapy, with three treatments being approved by the European Medicines Agency and the US Food and Drug Administration and a flood of candidate therapies
In a recent article in IPT magazine, Synpromics’ founder and Chief Scientific Officer Dr. Michael L Roberts discusses the current obstacles to overcome in optimising gene therapies.